Search results for "Lung neoplasms"

showing 10 items of 432 documents

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

2006

Abstract Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We investigated the association of survival with genetic polymorphisms in X-ray repair cross-complementing group 1 and group 3 (XRCC3), xeroderma pigmentosum group D (XPD), excision repair cross-complementing group 1, ligase IV, ribonucleotide reductase, TP53, cyclooxygenase-2, interleukin-6, peroxisome proliferator-activated receptor γ, epidermal growth factor, methylene-tetra-hydrofolate reductase and methionine synthase. Patients and methods: One hundred and thirty-five stage IV or IIIB (with malignant pleural effusion) NSCLC patien…

Xeroderma pigmentosumLung NeoplasmsDNA RepairGenotypeDeoxycytidineXRCC1Carcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCisplatin; DNA repair genes; Gemcitabine; Non-small-cell lung cancer; Polymorphisms; XRCC3Lung cancerXRCC3Survival analysisCisplatinPolymorphism GeneticDNA repair genesbusiness.industryHazard ratioHematologymedicine.diseaseSurvival AnalysisGemcitabineGemcitabineOncologyCancer researchCisplatinbusinessPolymorphismsNon-small-cell lung cancerNucleotide excision repairmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizu…

2017

Immune-checkpoint inhibitors represent the new standard of care in patients with advanced NSCLC who progressed after first-line treatment. This work aim to assess any difference in both efficacy and safety profiles among Nivolumab, Pembrolizumab and Atezolizumab in pre-treated NSCLC patients. Randomized clinical trials comparing immune-checkpoint inhibitor versus docetaxel in pre-treated patients with advanced NSCLC were included and direct comparison meta-analysis of selected trials have been performed. Subsequently the summary estimates of Nivolumab, Pembrolizumab and Atezolizumab emerging from the direct meta-analysis were selected to provide the pooled estimates of hazard ratio (HR) and…

atezolizumabCancer ResearchLung NeoplasmsAntineoplastic AgentsDocetaxelAntibodies Monoclonal HumanizedNSCLCClinical Trials Phase II as TopicCostimulatory and Inhibitory T-Cell ReceptorsCarcinoma Non-Small-Cell LungPDL1HumansRandomized Controlled Trials as TopicnivolumabIncidenceAntibodies MonoclonalPneumoniaSurvival AnalysisPD1Treatment OutcomeClinical Trials Phase III as TopicOncologyimmune-checkpointTaxoidsatezolizumab; immune-checkpoint; nivolumab; NSCLC; PD1; PDL1; pembrolizumab; Oncology; Cancer Researchpembrolizumab
researchProduct

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized …

2008

Summary Purpose A phase III randomized trial was carried out to compare two schedules of the vinorelbine (VNR)–cisplatin (CDDP) regimen in patients with locally advanced unresectable poor prognosis stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL). Patients and methods Eligible patients were randomized to receive: (a) VNR 25 mg/m 2 on day 1, 8 and 15 plus CDDP 100 mg/m 2 on day 1 every 4 weeks or (b) VNR 30 mg/m 2 on day 1 and 8 plus CDDP 80 mg/m 2 on day 1 every 3 weeks. All patients were chemotherapy-n…

inorganic chemicalsPulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyRandomizationLung NeoplasmsVinorelbineVinblastineGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerProspective cohort studyneoplasmsAgedNeoplasm StagingChi-Square Distributionbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineSurgeryRegimenLogistic ModelsTreatment OutcomeOncologyItalyDisease ProgressionQuality of LifeFemaleCisplatinbusinessFebrile neutropeniamedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas

2019

C1q is the first subcomponent of the classical pathway of the complement system and belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse range of immune and non-immune functions in a complement-dependent as well as -independent manner. Being a pattern recognition molecule of the innate immunity, C1q can recognize a number of self, non-self and altered-self ligands and bring about effector mechanisms designed to clear pathogens via opsonisation and inflammatory response. C1q is locally synthesized by macrophages and dendritic cells, and thus, can get involved in a range of biological processes, such as angiogenesis and tissue remodeling, immune modulation, and immu…

lcsh:Immunologic diseases. Allergy0301 basic medicinetumorLung NeoplasmsMicroenvironmentPrognosiImmunologyComplementBreast Neoplasmschemical and pharmacologic phenomenaKaplan-Meier EstimateBiology03 medical and health sciencesClassical complement pathway0302 clinical medicineImmune systemimmune system diseasesmedicineHumansImmunology and Allergycomplementclassical pathwayskin and connective tissue diseasesC1qOriginal ResearchTumorInnate immune systemEffectorComplement C1qComputational BiologyCancerPrognosismedicine.diseasemicroenvironmentKidney NeoplasmsComplement systemClear cell renal cell carcinomaC1q; Classical pathway; Complement; Microenvironment; Prognosis; Tumor030104 developmental biologyClassical pathwayCancer researchAdenocarcinomaprognosislcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

The Contribution of Cell Blocks in the Diagnosis of Mediastinal Masses and Hilar Adenopathy Samples from Echobronchoscopy

2014

medicine.medical_specialtyHilar adenopathyLung Neoplasmsbusiness.industryGeneral Medicine03 medical and health sciences0302 clinical medicineText mining030228 respiratory system030220 oncology & carcinogenesisMediastinal DiseasesmedicineHumansRadiologybusinessLymphatic DiseasesCell blockArchivos de Bronconeumología (English Edition)
researchProduct

Automatic detection of lung nodules in CT datasets based on stable 3D mass–spring models

2012

We propose a computer-aided detection (CAD) system which can detect small-sized (from 3 mm) pulmonary nodules in spiral CT scans. A pulmonary nodule is a small lesion in the lungs, round-shaped (parenchymal nodule) or worm-shaped (juxtapleural nodule). Both kinds of lesions have a radio-density greater than lung parenchyma, thus appearing white on the images. Lung nodules might indicate a lung cancer and their early stage detection arguably improves the patient survival rate. CT is considered to be the most accurate imaging modality for nodule detection. However, the large amount of data per examination makes the full analysis difficult, leading to omission of nodules by the radiologist. We…

medicine.medical_specialtyLung NeoplasmsDatabases FactualHealth InformaticsCADModels BiologicalSensitivity and SpecificityImaging Three-DimensionalSegmentationLung nodulemedicineFalse positive paradoxSegmentation; Lung nodules; Active contours models;Computer tomography (CT); Mass–spring models; Spline curves; Image featuresHumansSegmentationDiagnosis Computer-AssistedStage (cooking)Lung cancerComputer tomography (CT)business.industryNodule (medicine)Image featuresSpline curvemedicine.diseaseSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Computer Science ApplicationsRegion growingMass–spring modelRadiologyTomographymedicine.symptombusinessTomography Spiral ComputedAlgorithmsActive contours model
researchProduct

Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients

2021

Introduction: Lung cancer is the deadliest and most prevalent cancer worldwide. Lung cancer treatments have different characteristics and are associated with a range of benefits and side effects for patients. Such differences may raise uncertainty among drug developers, regulators, payers, and clinicians regarding the value of these treatment effects to patients. The value of conducting patient preference studies (using qualitative and/or quantitative methods) for benefits and side effects of different treatment options has been recognized by healthcare stakeholders, such as drug developers, regulators, health technology assessment bodies, and clinicians. However, evidence-based guidelines …

medicine.medical_specialtyLung NeoplasmsDecision Making03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingCarcinoma Non-Small-Cell LungNominal group techniqueMethodsmedicineHumans030212 general & internal medicineLung cancerQualitative ResearchReimbursementpatient involvementbusiness.industrylcsh:Public aspects of medicinePublic Health Environmental and Occupational HealthHealth technologyCancerPatient Preferencelcsh:RA1-1270medicine.diseaseFocus groupdrug developmentlung cancerDrug developmentnominal group technique030220 oncology & carcinogenesisFamily medicinefocus group discussiondrug decision-makingPublic Healthbusinesspatient preferencesQualitative researchpatient-centered research
researchProduct

Refractory Death Rattle: Deep Aspiration Facilitates the Effects of Antisecretory Agents

2011

Anticholinergic drugs, including atropine, hyoscine butylbromide, and scopolamine, have been shown to be equally effective in the treatment of death rattle. However, anticholinergic drugs may only be effective in reducing the production of further secretions, rather than eliminating the existing ones. A case is described in which a preventive procedure was undertaken to carefully eliminate secretions before starting anticholinergic drugs. Airway aspiration under light anesthesia removed secretions before starting anticholinergic drugs. Low doses of propofol were given intravenously to make a laryngoscopy feasible, allowing the complete aspiration of large amounts of tracheal secretions. No …

medicine.medical_specialtyLung NeoplasmsLaryngoscopyPainCholinergic AntagonistsFatal OutcomeRefractoryIntervention (counseling)Administration InhalationmedicineHumansDeath rattleIntensive care medicineGeneral NursingAgedRespiratory SoundsRetrospective StudiesTerminal Caremedicine.diagnostic_testbusiness.industryAntisecretory agentsPharyngeal DiseasesDeathAtropineDyspneaAnesthesiology and Pain MedicineAnesthesiaRespiratory MechanicsFemaleNeurology (clinical)medicine.symptomPropofolbusinessAirwaymedicine.drugJournal of Pain and Symptom Management
researchProduct

Translocation (10;11;22)(p14;q24;q12) Characterized by Fluorescence in Situ Hybridization in a Case of Ewing's Tumor

2001

It is well recognized that the identification by classic cytogenetics of t(11;22)(q24;q12) is a useful aid in the accurate diagnosis of Ewing's sarcoma and related tumors. This translocation induces the EWS/FLI-1 fusion transcript, which can be detected by reverse transcription-polymerase chain reaction. Recent studies have also used fluorescence in situ hybridization (FISH) to demonstrate the translocation. The authors coupled classic cytogenetics and FISH on tumor cells from the original specimen, the local recurrence, and the pulmonary metastasis as well as from the xenografted tumors in a case of extraosseous Ewing's sarcoma. FISH analysis not only confirmed the cytogenetic results but …

medicine.medical_specialtyLung NeoplasmsOncogene Proteins FusionChromosomes Human Pair 22Bone NeoplasmsChromosomal translocationSarcoma EwingBiologyTranslocation GeneticPathology and Forensic MedicineImmunoenzyme TechniquesFatal OutcomemedicineHumansChildMolecular BiologyIn Situ Hybridization FluorescenceLegmedicine.diagnostic_testChromosomes Human Pair 10Proto-Oncogene Protein c-fli-1Reverse Transcriptase Polymerase Chain ReactionChromosomes Human Pair 11CytogeneticsChromosomeEwing's tumorDNA NeoplasmSequence Analysis DNACell Biologymedicine.diseaseCombined Modality TherapyFusion transcriptKaryotypingCancer researchFemaleInterphaseSarcomaRNA-Binding Protein EWSTranscription FactorsFluorescence in situ hybridizationDiagnostic Molecular Pathology
researchProduct

A CAD system for nodule detection in low-dose lung CTs based on region growing and a new active contour model

2007

A computer-aided detection (CAD) system for the selection of lung nodules in computer tomography (CT) images is presented. The system is based on region growing (RG) algorithms and a new active contour model (ACM), implementing a local convex hull, able to draw the correct contour of the lung parenchyma and to include the pleural nodules. The CAD consists of three steps: (1) the lung parenchymal volume is segmented by means of a RG algorithm; the pleural nodules are included through the new ACM technique; (2) a RG algorithm is iteratively applied to the previously segmented volume in order to detect the candidate nodules; (3) a double-threshold cut and a neural network are applied to reduce…

medicine.medical_specialtyLung NeoplasmsRadiation DosageModels BiologicalEdge detectionImage processingMedical imagingmedicineHumansDiagnosis Computer-AssistedComputed radiographycomputer-aided diagnosis (CAD)Lungimage segmentationComputed tomographyActive contour modelImage segmentationbusiness.industrycomputed tomographyGeneral MedicineImage segmentationComputer-aided diagnosis (CAD)image processingROC CurveRegion growingComputer-aided diagnosisRadiologyTomographyNeural Networks Computercomputer-aided diagnosis (CAD)image processingcomputed tomographyimage segmentationNuclear medicinebusinessTomography X-Ray ComputedAlgorithms
researchProduct